Miyokard perfüzyon sintigrafisinde fotopeni gösteren pulmoner amfizem vakasi

Noncardiac findings are not common on routine myocard perfusion scintigraphy (MPS). In this case in which large photopenic area of left lung that corresponded to emphysema during the evaluation of unprocessed gated single photon emission computed tomography and raw data who received MPS and ventilation-perfusion scintigraphy for detecting the reason of chest pain was presented. We want to serve this case because of this incidental finding is not defined in the literature previously.Miyokard perfüzyon sintigrafisinde kalp dışı bulgular yaygın değildir. Bu vaka çalışmasında göğüs ağrısı nedeniyle miyokard perfüzyon sintigrafisi ve akciğer ventilasyon-perfüzyon sintigrafisi yapılan hastada işlemlenmemiş gated SPECT görüntülerinde ve ham dataların değerlendirilmesinde amfizemle uyumlu olarak sol akciğerde geniş fotopenik alan izlenmiştir. Bu tesadüfi bulgu daha önce literatürde tanımlanmadığı için sunulmak istenmiştir

Miyokard perfüzyon sintigrafisinde fotopeni gösteren pulmoner amfizem vakasi

Noncardiac findings are not common on routine myocard perfusion scintigraphy (MPS). In this case in which large photopenic area of left lung that corresponded to emphysema during the evaluation of unprocessed gated single photon emission computed tomography and raw data who received MPS and ventilation-perfusion scintigraphy for detecting the reason of chest pain was presented. We want to serve this case because of this incidental finding is not defined in the literature previously.Miyokard perfüzyon sintigrafisinde kalp dışı bulgular yaygın değildir. Bu vaka çalışmasında göğüs ağrısı nedeniyle miyokard perfüzyon sintigrafisi ve akciğer ventilasyon-perfüzyon sintigrafisi yapılan hastada işlemlenmemiş gated SPECT görüntülerinde ve ham dataların değerlendirilmesinde amfizemle uyumlu olarak sol akciğerde geniş fotopenik alan izlenmiştir. Bu tesadüfi bulgu daha önce literatürde tanımlanmadığı için sunulmak istenmiştir

Development and Evaluation of Sustained Release Tablet Formulations of Venlafaxine Hydrochloride

Aim: Depression is a mental disorder which affects more than 250 million people independently of their age. Venlafaxine is an antidepressant drug and used also for the treatment of panic attack and anxiety with fewer side effects than older antidepressant therapeutics. However, venlafaxine hydrochloride (VH) has a short half-life which requires three times dosing daily to maintain sufficient plasma drug concentration. The aim of this study is to develop sustained release VH tablets to be given once a day. Material and Methods: Polyethylene oxide, sodium alginate, hydroxypropyl methyl cellulose, guar gum and polyacrylic acid were used as controlled release agent. Tablets were prepared by direct compression method. Powder (angle of repose, flow rate, Carr index and Hausner ratio) and tablet (weight uniformity, hardness, friability,) characterizations were evaluated. In vitro release studies were carried out for 24 h and drug release kinetics were evaluated using different models. Results: All formulations showed suitable Carr index and Hausner ratio except the formulation prepared with guar gum. The tablets which had been manufactured via direct compression method were compared to the commercial tablet. Sustained release of VH was observed for all formulations. Based on the in-vitro dissolution studies, the drug release from F1 formulation which comprising HPMC and Carbopol polymers was found similar as compared to the commercial tablets. Conclusion: Directly compressed VH tablets could be a preferable alternative to the commercial tablets on behalf of patient compliance and fewer manufacturing steps compared to other production methods